The Medical Advisor

Cancer treatment is no longer one-dimensional. For decades, chemotherapy dominated oncology.  Today, treatment may include chemotherapy, targeted therapy, immunotherapy — or carefully designed combinations of all three. Yet confusion persists. Patients often ask: Is chemotherapy outdated? Is immunotherapy safer? Is targeted therapy more effective? Why do some people respond dramatically while others do not? This guide explains the science, clinical evidence, benefits, risks, and real-world decision-making framework behind modern oncology — grounded in standards used by the National Comprehensive Cancer Network and the American Society of Clinical Oncology. What is immunotherapy? Cancer cells are abnormal cells that replicate uncontrollably. Normally, your immune system destroys abnormal cells, but many types of cancer ce...

TL;DR  Best weight loss:  Mounjaro Best overall balance:  Wegovy Safest long-term data:  Semaglutide class Most overlooked truth:  benefits extend beyond weight Introduction: The GLP-1 Era Has Changed Medicine Over the past decade, a new class of medications— GLP-1 receptor agonists and incretin-based therapies —has fundamentally reshaped how we treat: Obesity Type 2 diabetes Cardiovascular risk Drugs like Ozempic, Wegovy, Mounjaro, and Trulicity are no longer niche therapies. They are now: Among the most prescribed metabolic drugs globally Central to what some call the “Ozempic economy” Positioned as potential lifespan-extending interventions But with rapid adoption comes confusion—and increasingly polarized narratives: One side: “These drugs are miracle breakthroughs” The other: “We don’t fully understand them—are they risky?” The truth sits in between. This guide cuts through both hype and fear to answer one question: Which GLP-1 drug is best—and what are th...

Semaglutide, known by the brand names Ozempic, Wegovy, Rybelsus and others, is the latest weight-loss craze to hit Hollywood and beyond. The prescription drug, which is administered via a weekly injection, is intended to treat Type 2 diabetes, but it’s widely used off-label for weight loss. They all belong to the same medication class — glucagon-like peptide-1 (GLP-1) agonists ( GLP-1 receptor agonists ).  GLP-1 agonists work by triggering insulin release, blocking sugar production in your liver, and making you feel full. But with all of these brands out there, how do you decide which is right for you? Let’s get to know some of the differences between these major GLP-1 agonist drugs. A 2021 study funded by Novo Nordisk, the drug’s maker, found using semaglutide once a week led to a 14.9% reduction in body weight among adults with obesity. There’s been such a rush on the drugs that the U.S. Food and Drug Administration lists both Ozempic and Wegovy a...

The GLP-1 Era: Inside the “Ozempic Economy” The phrase “Ozempic economy” captures a profound shift underway in healthcare, consumer behavior, and capital markets—driven by the explosive adoption of GLP-1 receptor agonists such as Ozempic , Wegovy , Mounjaro , and Zepbound . Originally developed for type 2 diabetes, these agents are now reshaping obesity treatment—and, by extension, food systems, retail, medtech, aesthetics, and public markets. What we’re witnessing is not just a drug cycle. It’s a metabolic reset with second-order economic consequences. In less than a decade, GLP-1 receptor agonists such as  Ozempic ,  Wegovy ,  Mounjaro , and  Zepbound  have transformed obesity from a stigmatized lifestyle issue into a pharmaceutical growth engine rivaling statins in economic magnitude. This 2026 authority report examines: The science behind GLP-1 drugs Clinical outcome data and durability Capital market consequences Impact on food, fitness, aesthetics, and in...

Introduction Pancreatic cancer  is among the most aggressive and difficult cancers to treat, particularly in its later stages. Approaches to improve pancreatic cancer therapy are essential as this disease has a very bleak outcome. Approximately 80% of pancreatic cancers are pancreatic ductal adenocarcinomas (PDAC). PDAC is a cancer which is difficult to effectively treat as it is often detected late in the disease process. Almost all PDACs (over 90%) have activating mutations in the  GTPase  gene  KRAS . Pancreatic cancer has a high mortality rate and is often resistant to conventional treatments. Standard therapeutic options include surgical resection, chemotherapy, and radiation therapy, yet survival rates remain low. Recently, alternative treatment strategies have gained interest, including the repurposing of existing drugs originally developed for non-cancer indications.  Given the limited success of conventional treatments, many patients and researchers are...